J
Judith A. Seidel
Researcher at Kyoto University
Publications - 11
Citations - 1074
Judith A. Seidel is an academic researcher from Kyoto University. The author has contributed to research in topics: Cancer & Immunotherapy. The author has an hindex of 5, co-authored 10 publications receiving 663 citations.
Papers
More filters
Journal ArticleDOI
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
TL;DR: The mechanisms of action and the limitations of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies which are the two types of checkpoint inhibitors currently available to patients are examined and the future avenues of their use in melanoma and other cancers are explored.
Journal ArticleDOI
The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis.
Atsushi Otsuka,Takashi Nomura,Pawinee Rerknimitr,Pawinee Rerknimitr,Judith A. Seidel,Tetsuya Honda,Kenji Kabashima,Kenji Kabashima +7 more
TL;DR: This review summarizes the etiopathogenesis of AD and provides the rationale for selecting a novel targeted therapy, Dupilumab, which has recently been developed for AD treatment.
Journal ArticleDOI
Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma
Yuki Honda,Atsushi Otsuka,Sachiko Ono,Yosuke Yamamoto,Judith A. Seidel,Satoshi Morita,Masahiro Hirata,Tatsuki R. Kataoka,Tatsuya Takenouchi,Kazuyasu Fujii,Takuro Kanekura,Yuko Okubo,Kenzo Takahashi,Teruki Yanagi,Daichi Hoshina,Hiroo Hata,Riichiro Abe,Taku Fujimura,Takeru Funakoshi,Koji Yoshino,Mamiko Masuzawa,Yasuyuki Amoh,Ryota Tanaka,Yasuhiro Fujisawa,Tetsuya Honda,Kenji Kabashima +25 more
TL;DR: The results suggest that PD-1/PD-L1 expression is related to CAS progression, and the treatment with anti-PD-1 antibodies could be a new therapeutic option for CAS.
Journal ArticleDOI
Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients
Yumi Nonomura,Atsushi Otsuka,Chisa Nakashima,Judith A. Seidel,Akihiko Kitoh,Teruki Dainichi,Saeko Nakajima,Yu Sawada,Shigeto Matsushita,Megumi Aoki,Tatsuya Takenouchi,Taku Fujimura,Naohito Hatta,Satoshi Kore-Eda,Satoshi Fukushima,Tetsuya Honda,Kenji Kabashima +16 more
TL;DR: It is suggested that Th9 cells, which produce IL-9, play an important role in the successful treatment of melanoma patients with nivolumab and represent a valid biomarker to be further developed in the setting of anti-PD-1 therapy.
Journal ArticleDOI
Treating tumors with immune checkpoint inhibitors: Rationale and limitations
TL;DR: The properties of PD-1 and CTLA-4 in physiological and tumor settings are summarized, and the treatment efficacy, side effects and biomarkers of their inhibitors are examined.